Effects of three antidiabetics on insulin and leptin in Chinese type 2 diabetes

Ming Zhao,Jia-Qing Shao,Hong Du

DOI: https://doi.org/10.1016/j.dsx.2009.08.003

2010-01-01

Abstract:Methods 80 type 2 diabetes men with overweight (body mass index BMI > 24 kg/m 2 ) and 35 type 2 diabetes men with normal body weight (BMI ≤ 24 kg/m 2 ) and 56 control subjects were enrolled in the study. We measured blood glucose, insulin, leptin, total cholesterol, LDL-C, HDL-C, triglycerides, fasting glucose, postprandial glycose, HbA1c and BMI before and after the administration of antidiabetic drugs. Results Compared with normal body weight, the levels of plasma insulin and leptin in overweight type 2 diabetes men were higher, after 3 months treatment, a significant increase in insulin and leptin levels was observed in overweight type 2 diabetes men in gliclazide group. Levels of leptin and insulin decreased in metformin and rosiglitazone groups, respectively. Conclusions We conclude that surfonylureas treatment leads to increased insulin and leptin levels in overweight type 2 diabetes men, metformin, or rosiglitazone treatment can reduce insulin and leptin levels, respectively, and effect of metformin on plasma leptin and insulin levels is more significant than that of rosiglitazone. Keywords Leptin Insulin Diabetes mellitus Antidiabetic drug 1 Introduction Leptin is a peiotropic molecule that regulates food intake and metabolism and endocrine responses and plays a regulatory role in hematopoiesis, inflammation, and immunity. The leptin levels were elevated in most patients with type 2 diabetes [1] , and were found strongly correlated with obesity, hyperinsulinemia, and insulin resistance-conditions [2] . Leptin also has been reported to upregulate peroxisome proliferator-activated receptor-γ (PPARγ) expression. Interestingly, PPARγ activation by thiazolidinediones inhibits leptin gene expression in vivo and in vitro. Thus, regulation and function of leptin and PPARγ are possibly interrelated and relevant in patients with type 2 diabetes. Some studies have shown that leptin, apart from involving in food intake and energy metabolism, also take part in vascular complication in type 2 diabetes by proliferation of endothelial cell of vascular with leptin receptor in itself. Surfonylureas, metformin and rosiglitazone are widely used in the treatment of type 2 diabetes, whether or how do they influence leptin levels in type 2 diabetes with or without overweight is not clear, therefore this study was carried out to evaluate the effects of metformin, rosiglitazone, gliclazide on circulating insulin and leptin levels in such men. The protocol was reviewed and approved by the Jinling Hospital Human Subjects Committees. 2 Materials and methods 2.1 Patients 115 newly diagnosed type 2 diabetic patients and 56 control subjects were included in the study. Patients with diabetic complications (retinopathy, neuropathy, and nephropathy) were excluded. All patients had normal blood pressure (blood pressure < 140/90 mmHg) and normal albuminuria (albuminuria < 30 mg/24 h). They had not taken any hypoglycemic medications at least 2 months before this study. The diagnosis of type 2 diabetes was made according to the criteria of the World Health Organization 1999. All patients were divided into two groups: (1) overweight group (BMI > 24 kg/m 2 , n = 80) and (2) normal body weight group (BMI ≤ 24 kg/m 2 , n = 35) according to the value of body mass index (BMI). For detail information see Table 1 . 2.2 Design The doses of hypoglycemic agents would be adjusted, or combined with these antidiabetic medicine until the goal of fasting blood glucose (FBG) less than 7.0 mmol/l and postprandial blood glucose (PBG) (2 h) less than 10.0 mmol/l was achieved in these patients. All patients select antidiabetic medicine according to the below principles: (1) for normal body weight diabetes, receiving gliclazide (80–240 mg/day) as a priority selection, and might add metformin when levels of blood glucose are higher than that of the goal, (2) for overweight patients, metformin or rosiglitazone was as priority selection, gliclazide may be added when levels of blood glucose are over goal, and (3) some patients would be excluded from our study if the goal of FBG and PBG had not reached using above treatment. 2.3 Biochemical measurements Before and after 3 months of treatment, BMI was calculated (kg/m 2 ), body weight and height were measured. Blood samples for leptin and insulin measurement were drawn into EDTA tubes after an 12 h overnight fast, immediately centrifuged, and plasma was stored −70 °C until assayed. The human insulin concentrations were determined using a radioimmunoassay kit purchased from China Institute of Atomic Energy, inter-assay coefficient of variation CV 7.2%, intra-assay CV 6.8%. The human leptin concentrations were determined by IRMA using kit purchased from Diagnostic Systems Laboratories Inc., Webster, USA, inter-assay CV 4.6%, intra-assay CV 4.2%. Serum levels of total cholesterol (TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) were measured using commercial reagents (Daiichi Pure Chemicals, Japan), and glucose, HbA1c were measured using commercial reagents (Randox, England) on a model 7600 automatic analyzer (Hitachi). 2.4 Statistical analysis All data are given as mean ± standard deviation (SD), clinical and laboratory parameters were analyzed by means of Student's t test. For correlation between the variables, F test was applied. Statistical significance was defined by values of p < 0.05. Metformin, rosiglitazone, gliclazide treatment were well tolerated by all subjects. A little of subjects suspended the therapy due to side effects, although some experienced transient diarrhea and flatulence during the first month of treatment. 3 Results It was observed in our study that levels of insulin and leptin in normal body weight group and overweight group are 16.6 ± 10.3 mIU/l versus 23.7 ± 14.1 mIU/l, p < 0.01; 4.1 ± 2.6 ng/ml versus 5.9 ± 3.6 ng/ml, p < 0.05. Furthermore, we found that, after administrating antidiabetic medicine, levels of insulin in normal body weight type 2 diabetes with monotherapy gliclazide (A′ group) increased significantly, p < 0.01; but no changes in leptin levels ( p = 0.08), there were also no changes in insulin and leptin levels in normal body weight type 2 diabetic patients with combination therapy gliclazide and metformin (B′ group). In overweight group, levels of insulin and leptin were higher after the administration of gliclazide (A group), p < 0.01; and lower in metformin (C group), rosiglitazone (D group), combination therapy metformin and gliclazide (B group), gliclazide and rosiglitazone (E group), metformin and rosiglitazone (F group), for detail information also see Table 2 and Fig. 1 . Among all groups, the levels of insulin and leptin are lowest in combination group (F group). But in all monotherapy groups, highest levels are found in A group, and lowest in C group. 4 Discussion In our study, we found that in overweight type 2 diabetes group, monotherapy (A group) can increase both value of levels of insulin and leptin, which indicate gliclazide not only stimulate insulin but also leptin. Haffner et al. [3] showed elevated leptin levels after sulfonylurea treatment in type 2 diabetes, and these patients had gained weight after treatment. We also observed that levels of insulin increase significantly in normal body weight type 2 diabetes, but no changes in leptin before and after monotherapy with gliclazide. Why did the phenomena happen in the same antidiabetic drug only in different body weight subjects with same type 2 diabetes? Exact mechanism remains unclear, we speculate that different effect of gliclazide on leptin may correlate with different basic insulin levels in different body weight. Because, some studies [4,5] found that, insulin can increase expression of leptin mRNA, increase circulating levels of leptin. β cells have leptin receptor in itself. Leptin, when combined with leptin receptor, depress the secretion of insulin from β cells, which means that excess circulating leptin levels depress secretion of insulin. It was speculated that when basic insulin level are not very high (for example, in normal weight type 2 diabetic patients), the increased insulin did not stimulate leptin secretion after the administration of gliclazide. But in overweight subjects with type 2 diabetes who have high circulating levels basal insulin, the increased insulin stimulates leptin secretion after the administration of gliclazide. At the same time, overt high levels of leptin depress insulin secretion from β cells in negative feedback means, which accelerated progress of diabetes. Metformin was widely used in the treatment of type 2 diabetes for many years, especially in overweight type 2 diabetes. We found that after the administration of metformin for 3 months, the levels of insulin and leptin are significantly lower than that before administration in both C group and B group. But the same phenomena did not appear in normal weight type 2 diabetes before and after administration in B group. Metin et al. [6] revealed that metformin, control diet, can decrease levels of leptin in both obese and non-obese type 2 diabetes. Furthermore, Mick et al. [7] reported that metformin decrease directly the secretion of leptin from adipocyte, but the exact mechanism is not clear now. Among all therapy groups, F group was found lowest in levels of insulin and leptin, next were C group and D group, respectively depending on drop of leptin and insulin after 3 months treatment. In E group, we observed fall of insulin levels ( p < 0.05), not leptin. All these results showed that rosiglitazone monotherapy not only decrease levels of blood glucose but also leptin and insulin. PPARγ is member of the steroid receptor superfamily and, as such, a ligand-activated transcription factor. Activators of PPARγ include high-affinity synthetic ligands, such as the antidiabetic thiazolidinediones, which are used for the treatment of type 2 diabetes in clinical in recent years [8] . Significant decreases in TNF-α and leptin levels were observed in patients with type 2 diabetes mellitus and metabolic syndrome treated with rosiglitazone and angiotensin type 1 receptor blockers after 6 months. In a previous study, the feedback was observed between PPARγ and leptin: leptin has been reported to upregulate PPARγ expression [9] , and activator of PPARγ activation by thiazolidinediones inhibits leptin gene expression in vivo and vitro [10,11] . Furthermore, PPARγ-ligands can inhibit endothelial cell migration which is induced by leptin [12] , the endothelial cell migration was connected with vascular complication of diabetes. These results implicated that leptin also takes part in occurrence and progress of diabetic vascular complication [13] . Besides the antiobesity actions, leptin has a wide range of actions including antidiabetic actions, which was reported to improve glucose and lipid metabolism in patients only with lipodystrophy. The effect of leptin on β-cell function remains unclear [14,15] . Leptin levels are closely associated with body fat mass. Leptin may participate in the pathogenesis of macrovascular disorders, and elevated leptin levels represent a cardiovascular risk factor independent of body weight. Similar to the insulin resistance indexes, leptinemia was strongly associated with the nutritional state. Hyperleptinemia and hyperinsulinemia may be risk markers of cardiovascular disease and may even participate in the pathogenesis of atherosclerosis. Overall, leptin participate in the development of diabetes and diabetic complication, so low circulating leptin levels has an important significance for preventing and treating diabetes. Different antidiabetic medicines have different effects on circulating levels of leptin in type 2 diabetes, and the same antidiabetic medicine also has different effects on circulating levels of leptin in different body weight. Sulfonylureas provoke insulin and leptin secretion and hypoglcemia; simultaneously, high levels of leptin can progress for diabetes itself. Both metformin and rosiglitazone, except for lowering levels of blood glucose, decrease the levels of insulin and leptin, and the effect of metformin is more significant than that of rosiglitazone. Both these antidiabetic medicines have new meaning for treating diabetes. Conflict of interest None. Acknowledgment We thank Dr. Genbao Feng for providing technical assistance. References [1] J. Seufert Leptin effects on pancreatic beta-cell gene expression and function Diabetes 53 Suppl. 1 2004 S152 S158 [2] R.B. Ceddia H.A. Koistinen J.R. Zierath G. Sweeney Analysis of paradoxical observations on the association between leptin and insulin resistance FASEB J 16 10 2002 1163 1176 [3] S.M. Haffner M. Hanefeld S. Fischer K. Fucker W. Leonhardt Glibenclamide, but not acarbose, increase leptin concentrations, parallel to changes in insulin in subjects with NIDDM Diabetes Care 20 1997 1430 1434 [4] P. Wellhoener B. Fruehwald-schultes W. Kern D. Dantz W. Kerner J. Born Glucose metabolism rather than insulin is a main determinant of leptin secretion in human (J) J Clin Endocrinol Metab 85 3 2000 1267 1271 [5] B. Schultes K.M. Oltmanns W. Kern H.L. Fehm J. Born A. Peters Modulation of hunger by plasma glucose and metformin J Clin Endocrinol Metab 88 3 2003 1133 1141 [6] O. Metin O. Cagatay N. Bingol I. Caglayan Ozdemir The effects of metformin and diet on plasma testosterone leptin levels in obese men Obesity Res 9 11 2001 662 667 [7] G.J. Mick X. Wang C. Ling Fu K.Z. Mccormick Inhibition of leptin secretion by insulin and metformin in cultured rat adipose tissue Biochim Biophys Acta 502 2000 426 432 [8] G. Derosa A.F. Cicero A. D’Angelo P.D. Ragonesi L. Ciccarelli M.N. Piccinni Telmisartan and Irbesartan therapy in Type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha Hypertens Res 29 11 2006 849 858 [9] H. Qian G.J. Hausman M.M. Compton M.S. Azain D.L. Hartzell C.A. Baile Leptin regulation of peroxisome proliferator-activated receptor-gamma, tumor necrosis factor, and uncoupling protein-2 expression in adipose tissues Biochem Biophys Res Commun 246 1998 660 667 [10] J. Ricusset J. Auwerx H. Vidd Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes Biochem Biophys Res Commun 265 1999 265 271 [11] P. De Vos A.M. Lefebvre S.G. Miller M. Guerre-Millo K. Wong R. Saladin Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma J Clin Invest 98 1996 1004 1009 [12] S. Goetze A. Bungenstock C. Czupalla F. Eilers P. Stawowy U. Kintscher leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands Hypertension 11 2002 748 754 [13] K. Ebihara T. Kusakabe M. Hirata H. Masuzaki F. Miyanaga N. Kobayashi Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy J Clin Endocrinol Metab 92 2 2006 532 541 [14] S. Bonin-Guillaume F.R. Herrmann D. Boillat I. Szanto J.P. Michel F. Rohner-Jeanrenaud Insulinemia and leptinemia in geriatric patients: markers of the metabolic syndrome or of undernutrition? Diabetes Metab 32 2006 236 243 [15] N. Satoh M. Naruse T. Usui T. Tagami T. Suganami K. Yamada Leptin-to-adiponectin ratio as a potential atherogenic index in obese type 2 diabetic patients Diabetes Care 27 2004 2488 2490